Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.

评估JYP0035 胶囊单药治疗晚期实体瘤患者的安全性、耐受性及药代动力学特征的开放、多中心临床研究

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:
What is the safety profile of JYP0035 when administered to these patients?
How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are:
The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis.
The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis.
Participants will:
Be treated with either a low-dose or high-dose of JYP0061.
Undergo efficacy and safety evaluations as stipulated in the trial protocol.